Pharmacological and genetic perturbation establish SIRT5 as a promising target in breast cancer
Yashira L. Negrón Abril(Agios Pharmaceuticals (United States)), Robert S. Weiss(Cornell University), Fangyu Wang(Affiliated Hospital of Jining Medical University), Ying‐Ling Chiang(Cornell University), Viviana I. Maymí(Cornell University), James Mullmann(Cornell University), Jun Young Hong(Central South University), Irma Fernández(Cornell University), Brenna C. Remick(University of California, Berkeley), Ravi Dhawan(Cornell University), Hening Lin(Howard Hughes Medical Institute), Bin He(Guiyang Medical University), Sushabhan Sadhukhan(Indian Institute of Technology Palakkad), Richard A. Cerione(Cornell University), Qingjie Zhao(Shanghai University of Traditional Chinese Medicine), Dennis A. Kutateladze(Massachusetts Institute of Technology), Teresa Southard(Cornell University), Bo Li(Southwest Medical University), Min Yang(Mianyang Central Hospital), Jing Hu(Integrated Chinese Medicine (China)), Jessica Jingyi Bai(Cornell University), Johan Auwerx(École Polytechnique Fédérale de Lausanne)
Cited by 87
Related Papers
Sirt5 Is a NAD-Dependent Protein Lysine Demalonylase and Desuccinylase
|Science|2011|1.4k
The Secret Life of NAD+: An Old Metabolite Controlling New Metabolic Signaling Pathways
|Endocrine Reviews|2010|879
Multi-omics analysis identifies ATF4 as a key regulator of the mitochondrial stress response in mammals
|The Journal of Cell Biology|2017|835
A guide to analysis of mouse energy metabolism
|Nature Methods|2011|816